Treatment of colorectal cancer (CRC)—the third leading cause of cancer-related death in the United States—remains challenging even today. But according to leading oncologists in the field, ...

Lynch syndrome (LS)–associated colorectal cancer (CRC) is characterized by mismatch repair-deficiency (MMR-D) and/or microsatellite instability (MSI). However, with increasing utilization of germline ...

Introduction Colorectal cancer (CRC) is the third most common cancer and second leading cause of cancer-related death in the United States with more than 149,500 new cases and 52,980 deaths estimated ...

Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA ...

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab. Patients with ...

Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...

Colorectal cancers (CRCs) with deficiency in the mismatch repair (MMR) genes, such as MLH1, MSH2 or MSH6, are classified as Lynch syndrome, and patients with such cancer are at higher risk for other ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Patients with MMR-deficient colorectal cancer showed a 62% ORR with Keytruda, compared to 0% in MMR-proficient patients. MMR-deficient tumors had a higher mutational burden, indicating a greater ...